Dare Bioscience, Inc.

DARESEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1401914

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$2.8M	—	$0.00	—	—
Research and Development Expense	$21.5M	$30.0M	$30.6M	$20.8M	$8.5M
Operating Expenses	$33.7M	$41.4M	$39.1M	$27.4M	$14.3M
Operating Income (Loss)	-$30.9M	-$31.4M	-$39.1M	-$27.4M	-$14.3M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$30.2M	-$30.9M	-$38.7M	-$27.4M	—
Income Tax Expense (Benefit)

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$21.3M	$43.8M	$55.8M	$7.6M	$7.4M
Assets, Current	$17.5M	$43.0M	$55.3M	$7.0M	$6.4M
Cash and Cash Equivalents, at Carrying Value	$10.5M	$34.7M	$51.7M	$4.7M	$4.8M
Liabilities	$26.3M	$32.7M	$17.1M	$8.7M	$7.0M
Liabilities, Current	$20.5M	$31.6M	$16.1M	$7.7M	$5.6M
Accounts Payable, Current	$3.4M	$2.0M	$2.1M	$1.0M	$1.1M
Stockholders' Equity Attributable to Parent	$11.1M	$38.8M	-$1.2M	$440.8K

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$38.9M	-$18.1M	-$28.8M	-$25.2M	-$13.3M
Net Cash Provided by (Used in) Investing Activities	-$629.4K	-$63.1K	-$14.5K	-$17.6K	$6.1M
Net Cash Provided by (Used in) Financing Activities	$15.6M	$1.3M	$75.8M	$25.1M	$5.2M
Payments to Acquire Property, Plant, and Equipment	$629.4K	$63.1K	$14.5K	$17.6K	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)